Adia Nutrition Inc. Announces Transformative 2025 Milestones and Strategic Progress Toward Nasdaq Uplisting
Adia Nutrition (OTCQB: ADIA) summarized 2025 milestones including a confirmed 200%+ Q3 revenue surge quarter-over-quarter with profit margins above 20%, accelerated commercial expansion, and steps toward Nasdaq uplisting. The company said it will file a Form 10 by end of November 2025 (SEC review period ~60 days) and expects Form 10 effectiveness by late January 2026. Other highlights: sales force tripled with four regional divisions, preferred‑vendor access to >4,000 personal injury physicians, progress toward insurer in‑network status, and a divestiture of Biolete Coffee while retaining an 18% equity stake.
Adia Nutrition (OTCQB: ADIA) ha riassunto le tappe del 2025, includendo una confermata impennata dei ricavi nel Q3 di oltre 200% trimestre su trimestre con margini di profitto superiori al 20%, accelerazione dell'espansione commerciale e passi verso l'uplist su Nasdaq. L'azienda ha dichiarato che presenterà un Form 10 entro la fine di novembre 2025 (periodo di revisione SEC ~60 giorni) e si aspetta l'efficacia del Form 10 entro la fine di gennaio 2026. Altri punti salienti: la forza vendita triplicata con quattro divisioni regionali, accesso come fornitore preferito a oltre 4.000 medici di lesioni personali, avanzamenti verso lo status di rete interna dell'assicuratore, e una cessione di Biolete Coffee mantenendo una partecipazione azionaria dell'18%.
Adia Nutrition (OTCQB: ADIA) resumió los hitos de 2025, incluida una subida confirmada de ingresos del 200%+ en el trimestre Q3 frente al trimestre anterior, con márgenes de beneficio superiores al 20%, expansión comercial acelerada y pasos hacia la cotización en Nasdaq. La compañía dijo que presentará un Formulario 10 para finales de noviembre de 2025 (período de revisión de la SEC ~60 días) y espera la eficacia del Form 10 para finales de enero de 2026. Otros puntos destacados: la fuerza de ventas se triplicó con cuatro divisiones regionales, acceso como proveedor preferente a más de 4,000 médicos de lesiones personales, progreso hacia el estatus de red interna de la aseguradora y la desinversión de Biolete Coffee manteniendo una participación del 18%.
Adia Nutrition (OTCQB: ADIA) 은 2025년의 주요 이정표를 요약했다. 분기 대비 3분기 매출 200%+ 급증과 20% 이상의 이익 마진, 가속된 상업 확장 및 나스닥 상장을 위한 조치를 포함한다. 회사는 2025년 11월 말까지 Form 10 작성을 제출할 것이며(SEC 심사 기간 약 60일), 2026년 1월 말까지 Form 10의 효력이 발효될 것으로 기대한다. 기타 하이라이트: 영업력이 네 지역으로 분할된 네 개의 부문과 함께 4,000명 이상의 개인 상해 의사에 대한 선호 공급업체 접근 권한, 보험사 네트워크 상태에 대한 진행, Biolete Coffee 매각 및 18%의 지분 유지.
Adia Nutrition (OTCQB: ADIA) a résumé les jalons 2025, dont une hausse confirmée des revenus au T3 de >200% trimestre sur trimestre avec des marges bénéficiaires de plus de 20%, une expansion commerciale accélérée et des étapes vers une cotation au Nasdaq. L'entreprise a déclaré qu'elle déposera un Form 10 d'ici la fin novembre 2025 (période de révision SEC ~60 jours) et prévoit l'efficacité du Form 10 d'ici la fin janvier 2026. Autres faits marquants : force de vente triplée avec quatre divisions régionales, accès en tant que fournisseur privilégié à plus de 4 000 médecins spécialisés en blessures personnelles, progrès vers le statut de réseau interne de l'assureur, et la cession de Biolete Coffee tout en conservant une participation de 18%.
Adia Nutrition (OTCQB: ADIA) fasste 2025er Meilensteine zusammen, darunter eine bestätigte Umsatzsteigerung im Q3 von über 200% gegenüber dem Vorquartal mit Gewinnmargen über 20%, eine beschleunigte kommerzielle Expansion und Schritte zur Nasdaq-Uplisting. Das Unternehmen gab an, dass es bis Ende November 2025 ein Form 10 einreichen wird (SEC-Prüfungszeit ~60 Tage) und rechnet damit, dass das Form 10 bis Ende Januar 2026 wirksam wird. Weitere Highlights: Die Vertriebsorganisation hat sich mit vier Regionalabteilungen vervielfacht, Zugang als bevorzugter Anbieter zu über 4.000 Ärzten für Personenschäden, Fortschritte beim Netzstatus des Versicherers, und der Verkauf von Biolete Coffee bei gleichzeitiger Beibehaltung einer 18%-igen Beteiligung.
Adia Nutrition (OTCQB: ADIA) تلخص معالم 2025 بما في ذلك زيادة الإيرادات في الربع الثالث بنحو >200% مقارنة بالربع السابق مع هوامش ربح تفوق 20%، وتوسع تجاري متسارع وخطوات نحو الإدراج في ناسداك. قالت الشركة إنها ستقدم نموذج Form 10 بنهاية نوفمبر 2025 (فترة مراجعة SEC تقارب 60 يوماً) وتتوقع فاعلية النموذج Form 10 بحلول أواخر يناير 2026. نقاط بارزة أخرى: تضاعف فريق المبيعات مع أربع مناطق إقليمية، وصول كمورد مفضل لأكثر من 4,000 طبيب مختص في الإصابات الشخصية، التقدم نحو وضع الشبكة الداخلية للمؤمِّن، وتصفية Biolete Coffee مع الاحتفاظ بحصة ملكية نسبتها 18%.
- Q3 revenue +200%+ quarter-over-quarter
- Profit margins > 20%
- Form 10 filing planned by end of November 2025
- Sales force tripled and four regional divisions launched
- Preferred vendor access to 4,000+ personal injury physicians
- None.
Winter Park, Florida--(Newsfile Corp. - November 5, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today recaps its pivotal year-to-date achievements, marked by explosive revenue growth, strategic divestitures, and decisive steps toward full SEC reporting and a Nasdaq listing.
2025 Key Milestones
Q3 Revenue Surges Over
200% Quarter-Over-Quarter: On October 8, preliminary results showed revenue growth exceeding100% , followed by the October 28 announcement confirming a200% + increase with profit margins above20% , driven by strong demand for Adia Med clinics and Adia Labs regenerative products.
Source: NewsfileSEC Form 10 Scheduled for Filing – Nasdaq Pathway Activated: Adia Nutrition has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). Adia expects to submit the Form 10 by the end of November 2025, with the SEC review and recognition period set at 60 days.
Source: NewsfileSales Force Tripled with Regional Expansion: Early 2025 saw the company scale its sales infrastructure by tripling its team and launching four dedicated regional divisions (East Coast, West Coast, Central U.S., and International) to accelerate nationwide and global distribution of Adia Vita, AdiaLink, and other high-margin therapies.
Source: NewsfileMajor Insurance In-Network Progress: Adia Med advanced negotiations to secure in-network provider status with leading insurers including Medicare, Medicaid, Humana, Cigna, and Florida Blue, unlocking reimbursement pathways for AHSCT, TPE, and stem cell therapies at scale.
Source: NewsfileStrategic Entry into
$50B Personal Injury Market: In August, Adia Labs became a preferred vendor for the PI Doctors Elite Community, gaining direct access to over 4,000 personal injury physicians nationwide to integrate Adia Vita and AdiaLink into injury recovery protocols.
Source: NewsfileShare Structure Optimization & Governance: The company completed a share retirement initiative and ongoing capital structure review to enhance transparency, reduce dilution, and align with best-in-class governance standards.
Source: NewsfileFocused Divestiture of Biolete Coffee: Adia divested its non-core coffee subsidiary to Cement Factory LLC, retaining an
18% equity stake, while redirecting full resources toward high-growth regenerative medicine and clinical expansion.
Source: Newsfile
CEO Commentary
"2025 has been a defining year of execution and momentum," said Larry Powalisz, CEO of Adia Nutrition. "From tripling sales capacity to achieving
Strategic Outlook
Adia Nutrition is now laser-focused on:
Achieving full SEC Form 10 effectiveness by late January 2026
Securing Nasdaq listing for enhanced liquidity and institutional investment
Expanding clinic network and insurer integrations to scale high-margin therapies
Driving product revenue through expanded U.S. and international sales channels
Upholding transparency and governance to build long-term investor confidence
With a streamlined structure, record profitability, and a clear path to major exchange listing, Adia Nutrition is positioned for sustained growth and value creation.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273008
FAQ
What did Adia Nutrition (ADIA) report for Q3 2025 revenue growth?
When will Adia Nutrition (ADIA) file its SEC Form 10 for Nasdaq listing?
What timeline did Adia Nutrition (ADIA) give for Form 10 effectiveness and Nasdaq steps?
How has Adia Nutrition (ADIA) expanded its commercial footprint in 2025?
What progress did Adia Nutrition (ADIA) report on insurer reimbursement?
Did Adia Nutrition (ADIA) make any divestitures in 2025?
